C4 Therapeutics, Inc.

NASDAQ:CCCC

Biotechnology

Healthcare
$2.48 +2.06%

+$0.08 today

Market cap
$325.01M
Beta
2.93
P/E (TTM)
-4.9
EPS (TTM)
-$0.82
52W Low $1.36High $4.60

Volume 2.75M

Average 2.76M

CCCC Other Non-Cash Items

Other non-cash adjustments that reconcile net income to operating cash flow.

C4 Therapeutics, Inc.NASDAQ: CCCC

Other Non-Cash Items · Q1 FY2026 · quarter ended Mar 2026

Other non-cash items dips below year-ago levels

Q1 FY2026 other non-cash items of $382K fell 57.2% year over year, behind the +931.6% change in trailing-twelve-month other non-cash items. Sequentially, it fell 34.9% from the prior quarter. Over 3 fiscal years it compounded at +25.6% a year.

Context

  • Other non-cash items amounted to 40.4% of revenue in FY2025, up 37.5 pp from a year earlier.
  • Other non-cash items increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -57.2% toward the trailing-twelve-month pace of +931.6%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$382K-34.9% QoQ
Last fiscal yearDec 2025
$14.52M+1308.7% YoY
LTMMar 2026
$17.54M+931.6% YoY
Other Non-Cash Items past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-57.2%——
1 year+1308.7%——
3-year CAGR+25.6%——
5-year CAGR——
10-year CAGR——

Other Non-Cash Items history

USD · from the cash flow

Latest · FY2025
14.52M USD
Year-over-year change
+1308.7%
4-year CAGR
+61.5%

Other Non-Cash Items vs competitors

How CCCC compares with its peers on the latest reported figures

  • Peers report in different currencies, so other non-cash items is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +931.6% is the 2nd highest of 9, against a peer median of +196.3%.
  • Other non-cash items amounts to 50.3% of revenue for CCCC, versus a peer median of 253.9%.
CCCC Competitors
Other Non-Cash Items for CCCC and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ARMPArmata Pharmaceuticals, Inc.LTM Mar 2026$253.45M USD+784.2%—8568.3%
CCCCC4 Therapeutics, Inc.LTM Mar 2026$17.54M USD+931.6%+25.6%50.3%
IMDXInsight Molecular Diagnostics Inc.LTM Mar 2026$15.81M USD-55.3%+14.2%811.1%
SGMOSangamo Therapeutics, Inc.LTM Mar 2026$15.4M USD+3205.6%—44.6%
MISTMilestone Pharmaceuticals Inc.LTM Mar 2026$8.26M USD+157.5%+340.4%463.2%
CDXSCodexis, Inc.LTM Mar 2026$4.93M USD-58.9%—6.3%
MOLNMolecular Partners AGLTM Mar 2026CHF 4.3M CHF+257.9%——
OABIOmniAb, Inc.LTM Mar 2026$2.65M USD+166.9%+95.9%9.2%
PEPGPepGen Inc.LTM Mar 2026$2.6M USD+225.7%——
Peer median (excluding CCCC) —+196.3%+95.9%253.9%

Competitors are the stored peer set for CCCC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(83.89M)(128.18M)(132.49M)(105.32M)(104.99M)
Depreciation & Amortization1.49M1.68M1.88M1.82M1.96M
Deferred Income Tax1.88M0000
Stock-Based Compensation21.51M30.02M27.24M29.66M19.1M
Change in Working Capital(30.09M)(16.78M)(6.94M)7.65M(29.28M)
Accounts Receivables(1.23M)4.24M(10.33M)8.7M701K
Inventory(2.63M)0000
Accounts Payables(1.18M)(3.33M)273K(119K)(468K)
Other Working Capital(25.05M)(17.69M)3.12M(930K)(29.52M)
Other Non-Cash Items2.13M7.32M3.48M1.03M14.52M
Operating Cash Flow(86.97M)(105.94M)(106.84M)(65.16M)(98.69M)
Capital Expenditures(1.28M)(5.5M)(1.71M)(180K)(607K)
Acquisitions (Net)188.06M(63.92M)000
Purchases of Investments(537.74M)(219.53M)(129.9M)(284.32M)(227.07M)
Sales of Investments349.68M283.45M289.96M233.23M219.08M
Other Investing Activities(188.06M)63.92M000
Investing Cash Flow(189.34M)58.42M158.35M(51.27M)(8.6M)
Debt Repayment00(12.5M)00
Common Stock Issued169.47M777K57.67M44.37M126.32M
Common Stock Repurchased00(110K)(194K)(193K)
Dividends Paid00000
Other Financing Activities1.94M370K426K1.16M274K
Financing Cash Flow171.4M1.15M45.49M45.34M126.4M
Effect of Forex Changes00000
Net Change in Cash(104.9M)(46.37M)97M(71.09M)19.1M
Free Cash Flow(88.24M)(111.44M)(108.55M)(65.34M)(99.3M)

C4 Therapeutics, Inc.

NASDAQ:CCCC

Intrinsic Alpha fair value

Locked

Current Price

$2.48

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.